Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Acarbose capsule pharmaceutical composition

A technology of acarbose and capsules, applied in the field of medicine, can solve the problems of inconvenience in taking, large differences, poor fluidity of acarbose and the like

Active Publication Date: 2017-03-29
HANGZHOU ZHUYANGXIN PHARMA
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Disadvantages of this method: acarbose has poor fluidity, even if lubricant is added, its fluidity cannot be improved well, and the main drug and auxiliary materials are mixed and pressed into tablets. The raw material of acarbose is relatively light, and the auxiliary materials After mixing directly, and then compressing the tablets, there will be large differences in the tablets, and even unqualified phenomena, and powder spraying will occur during the tableting process, which cannot guarantee the eligibility of the tablet weight
It is believed that the invention overcomes the disadvantages of inconvenient administration of existing tablets and capsules, and provides an easier-to-administer acarbose preparation that disintegrates rapidly in the oral cavity and does not require water

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acarbose capsule pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Embodiment 1: Preparation of acarbose capsules

[0100] formula:

[0101] Acarbose 50mg microcrystalline cellulose 20mg corn starch 90mg Modified pregelatinized starch 40mg silica 1mg Magnesium stearate 1.5mg

[0102] Preparation method:

[0103] (1) Mix acarbose and the microcrystalline cellulose of the prescribed amount evenly, and spray concentration>98% ethanol (the weight ratio of acarbose to the ethanol is 50:4) into the mixed powder under high-speed mixing state. ), the resulting mixture is pre-compressed into tablets with an extruder, and then the tablets are broken into granules, dried to remove ethanol, and then the granules are pulverized into fine powders crossing 80 mesh sieves;

[0104] (2) Mix other diluents that have been pulverized and crossed 80 mesh sieves with the mixed powder obtained in step (1) in advance;

[0105] (3) mixing the glidant and lubricant with the mixed powder obtained in step (2)...

Embodiment 2

[0108] Embodiment 2: preparation of acarbose capsules

[0109] formula:

[0110] Acarbose 50mg microcrystalline cellulose 20mg Cassava starch 87.5mg Modified pregelatinized starch 40mg silica 1mg Magnesium stearate 1.5mg

[0111] Preparation method:

[0112] (1) Mix acarbose and the microcrystalline cellulose of the prescribed amount evenly, and spray concentration>98% ethanol (the weight ratio of acarbose to the ethanol is 50:3) into the mixed powder under high-speed mixing state ), the resulting mixture is pre-compressed into tablets with an extruder, and then the tablets are broken into granules, dried to remove ethanol, and then the granules are pulverized into fine powders crossing 80 mesh sieves;

[0113] (2) Mix other diluents that have been pulverized and crossed 80 mesh sieves with the mixed powder obtained in step (1) in advance;

[0114] (3) mixing the glidant and lubricant with the mixed powder obtained in ste...

Embodiment 3

[0117] Embodiment 3: Preparation of acarbose capsules

[0118] formula:

[0119] Acarbose 50mg microcrystalline cellulose 15mg Potato starch 95mg Modified pregelatinized starch 45mg silica 0.5mg Magnesium stearate 1.2mg

[0120] Preparation method:

[0121] (1) Mix acarbose and the microcrystalline cellulose of the prescribed amount evenly, and spray ethanol with a concentration>98% into the mixed powder under high-speed mixing state (the weight ratio of acarbose and the ethanol is 50:2 ), the resulting mixture is pre-compressed into tablets with an extruder, and then the tablets are broken into granules, dried to remove ethanol, and then the granules are pulverized into fine powders crossing 80 mesh sieves;

[0122] (2) Mix other diluents that have been pulverized and crossed 80 mesh sieves with the mixed powder obtained in step (1) in advance;

[0123] (3) mixing the glidant and lubricant with the mixed powder obtained ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an acarbose capsule pharmaceutical composition. Concretely, the acarbose capsule pharmaceutical composition comprises a capsule shell and powdery or granular filler wrapped in the capsule shell, wherein the capsule shell is made by taking gelatin, hydroxypropyl methyl cellulose, algal polysaccharides, pectin or carboxymethyl cellulose as a main component, the filler comprises an active substance, a diluent, a lubricating agent and a glidant, and the active substance is acarbose. The acarbose capsule pharmaceutical composition has excellent pharmaceutical property.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a pharmaceutical composition, in particular to a pharmaceutical preparation in the form of a hard capsule, in particular to an acarbose capsule pharmaceutical composition. The invention also relates to a process for their preparation. Background technique [0002] Diabetes Mellitus (DM) is a group of metabolic diseases characterized by chronic increase in blood glucose (referred to as blood sugar) level, which is caused by defects in insulin secretion and / or action. Long-term carbohydrate, fat, and protein metabolic disorders can cause multi-system damage, leading to chronic progressive lesions, functional decline, and failure of tissues and organs such as eyes, kidneys, nerves, heart, and blood vessels. Severe metabolic disorders can occur in severe conditions or stress, such as diabetic ketoacidosis (DKA), hyperglycemia and hyperosmolar state, etc. The disease reduces the quali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/48A61K31/7036A61K47/42A61K47/38A61K47/36A61P3/10
Inventor 李阅东唐建飞沈如杰何海珍马雯霞姚成娥张群赵福斌张婧
Owner HANGZHOU ZHUYANGXIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com